Clinical Trials Logo

Loiasis clinical trials

View clinical trials related to Loiasis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05085665 Completed - Loiasis Clinical Trials

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Start date: July 30, 2021
Phase: Phase 4
Study type: Interventional

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

NCT ID: NCT04049630 Completed - Loiasis Clinical Trials

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

EOLoa
Start date: January 16, 2021
Phase: Phase 2
Study type: Interventional

This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.

NCT ID: NCT01111305 Completed - Loiasis Clinical Trials

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. This randomized, placebo-controlled, double-blind pilot study (conducted at the NIH Clinical Center) will assess whether and to what extent the administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3 times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on microfilarial clearance.